Literature DB >> 18340169

A clinical and biochemical critical pathway for the evaluation of patients with suspected acute congestive heart failure: The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) algorithm.

Aaron L Baggish1, Renee Cameron, Saif Anwaruddin, Annabel A Chen, Daniel G Krauser, Roderick Tung, James L Januzzi.   

Abstract

Dyspnea is a primary clinical manifestation of acute congestive heart failure (CHF) among patients presenting to the emergency department (ED). Unfortunately, other critical illnesses, including acute coronary syndromes, pulmonary embolism, chronic obstructive pulmonary disease, and pneumonia, may present with clinical symptoms and signs similar to acute CHF. N-terminal pro-brain natriuretic peptide (NT-proBNP) has proven to be a powerful tool in the diagnostic assessment of dyspnea as a result of its ability to confirm or exclude the presence of acute CHF. However, many of the disorders that mimic acute CHF may result in elevated NT-proBNP levels as well. Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study recently demonstrated that a strategy integrating NT-proBNP testing into routine clinical assessment demonstrated a better diagnostic yield than each strategy used in isolation. We present a diagnostic algorithm integrating NT-proBNP testing with clinical assessment for use in routine clinical practice.

Entities:  

Year:  2004        PMID: 18340169     DOI: 10.1097/01.hpc.0000145817.68289.a2

Source DB:  PubMed          Journal:  Crit Pathw Cardiol        ISSN: 1535-2811


  7 in total

1.  Elevated N-terminal pro-brain natriuretic peptide in Mycobacterium tuberculosis pulmonary infection without myocardial dysfunction.

Authors:  Simona L Bar; Naser Sayeh; Andrew P Ignaszewski
Journal:  Can J Cardiol       Date:  2009-04       Impact factor: 5.223

Review 2.  Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure.

Authors:  A Palazzuoli; M Gallotta; I Quatrini; R Nuti
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

Review 3.  Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure.

Authors:  Jun R Chiong; Geoffrey T Jao; Kirkwood F Adams
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

4.  Nonheart failure-associated elevation of amino terminal pro-brain natriuretic peptide in the setting of sepsis.

Authors:  Simona L Bar; Elizabeth Swiggum; Lynn Straatman; Andrew Ignaszewski
Journal:  Can J Cardiol       Date:  2006-03-01       Impact factor: 5.223

5.  Validity of Amino Terminal pro-Brain Natiuretic Peptide in a Medically Complex Elderly Population.

Authors:  Mazhar A Afaq; Azadeh Shoraki; Oleg Ivanov; Janardhan Srinivasan; Lawrence Bernstein; Stuart W Zarich
Journal:  J Clin Med Res       Date:  2011-07-26

6.  Physiology and clinical significance of natriuretic hormones.

Authors:  Sandeep Chopra; Davis Cherian; Prashant Paul Verghese; Jubbin J Jacob
Journal:  Indian J Endocrinol Metab       Date:  2013-01

7.  The ability of heart failure specialists to accurately predict NT-proBNP levels based on clinical assessment and a previous NT-proBNP measurement.

Authors:  Tara L Sedlak; Mann Chandavimol; Anna Calleja; Catherine Clark; Margaret Edmonds; Aihua Pu; Karin H Humphries; Andrew Ignaszewski
Journal:  Open Cardiovasc Med J       Date:  2008-06-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.